2616 — CStone Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$7.77bn
- HK$6.36bn
- CNY269.58m
Brief: CStone Pharmaceuticals Announces Delay In Publication Of Annual Results Announcement
Brief: Cstone Pharmaceuticals Says China's Nmpa Has Approved Supplemental NDA Of Selective Rearranged During Transfection Inhibitor Gavreto
Brief: Cstone Pharmaceuticals Announced Acceptance Of New Drug Application For Pralsetinib
Brief: Cstone Pharmaceuticals Says China NMPA Approved New Drug Application Of Tibsovo For Treatment Of Acute Myeloid Leukemia
Brief: Cstone Pharmaceuticals Says Drug Met Endpoint Of Overall Survival In First-Line Treatment
Brief: Cstone Pharmaceuticals Announces IND Approval For Study In China Of Lorlatinib
Brief: Cstone Pharmaceuticals Announces IND Approval Of CS5001 Ror1-Targeting Adc By U.S. FDA
Brief: Cstone Pharmaceuticals Announced The IND Approval Of CS5001 By U.S. Food And Drug Administration
HK-listed CStone Pharmaceuticals drops most in nearly 3 years
Brief: CStone Says Ayvakit NDA Approved In HK, China To Treat PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
Ligand Pharma rises as Chinese partner gets approval for lung cancer drug
HK-listed CStone Pharma jumps most in nearly 16 weeks on new drug approval
Gavreto wins conditional EU approval to treat form of lung cancer -Roche (updated)
Brief: CStone Pharmaceuticals Says Co & Dotbio Pte Ltd Have Entered Into Collaboration Agreement On November 8
Brief: Cstone Pharmaceuticals Receive China NMPA IND Acceptance For Lorlatinib In Patients With Ros1-Positive Advanced NSCLC
Brief: Cstone Pharmaceuticals Got Investigational New Drug Approval By Nmpa For Cs2006/Nm21-1480
China's CStone Pharma set for best day in over 7 weeks on new drug application
Brief: CStone Pharmaceuticals Posts HY IFRS Revenue RMB79.4 MLN
HK-listed CStone Pharma jumps most in 6 wks on benchmark index inclusion